![](/img/cover-not-exists.png)
Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer
Chien, A. J., Munster, P. N., Melisko, M. E., Rugo, H. S., Park, J. W., Goga, A., Auerback, G., Khanafshar, E., Ordovas, K., Koch, K. M., Moasser, M. M.Volume:
32
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.2013.52.1161
Date:
May, 2014
File:
PDF, 449 KB
english, 2014